Anti-Human CD11a (Efalizumab) Dylight® 488
|Amount :||50 µg|
|Isotype :||Human IgG1k|
|Content :||Concentration : 0.2 mg/ml
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
|Storage condition :||This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.|
|Alternative Name :||ITGAL; integrin alpha L; LFA-1; LFA1A|
|Immunogen Information :||Human CD11a|
Expression Host : HEK-293
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Efalizumab. Clone hu1124 recognizes human CD11a. This product is for research use only.
CD11a and CD18 are the Integrin alpha-L and beta-2 subunits that combine to form LFA-1, a glycoprotein and a member of the Integrin family. The Integrin alpha-L/beta-2 complex is a receptor for ICAM1, ICAM2, ICAM3, ICAM4 and F11R. LFA-1 participates in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells. Efalizumab binds to the CD11a subunit of LFA-1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Anti-Human CD11a (Efalizumab) utilizes the same variable regions from the therapeutic antibody Efalizumab making it ideal for research projects.
The suggested concentration for Efalizumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.